Full Press Release Details
ABBOTT PARK, Ill., March 6, 2019 /PRNewswire/ -- Key medical devices across Abbott's (NYSE: ABT ) cardiovascular portfolio will be highlighted in five late-breaking clinical trials at the American College of Cardiology's 68 th Annual Scientific Session (ACC 2019) from March 16 – 18 in New Orleans . The late-breaking studies showcase the depth and breadth of the company's cardiovascular portfolio, providing new data on outcomes with the following products: the MitraClip™ system for transcatheter mitral valve repair, the HeartMate 3™ heart pump, the CardioMEMS™ HF System for proactive heart failure monitoring, and the XIENCE drug eluting coronary stent.
Late-breaking data at the American College of Cardiology Scientific Sessions can change clinical practice and impact the way new therapies are accepted and utilized to improve patient care. For Abbott, ACC 2019 provides an opportunity to demonstrate how the company's therapies have led to dramatic improvements in the treatment of cardiovascular diseases. Data from these late-breaking trials may help physicians rethink what is possible in managing patients with coronary artery disease and heart failure.
"Heart disease impacts far too many patients and families worldwide," said Mark Carlson , M.D., divisional vice president and chief medical officer, Cardiac Arrhythmias and Heart Failure, Abbott. "Across Abbott we focus every day on developing the next breakthroughs in cardiovascular care. At ACC, we're excited to showcase several of our best-in-class technologies that are shaping how healthcare providers care for people with heart disease."
During ACC 2019, the following late-breaking data on Abbott technology will be presented in the Main Tent (Great Hall):
About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 103,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.